Form 4 for CRVS Corvus Pharmaceuticals, Inc.
Accepted 2024-05-07 00:00:00 ET · period of report 2024-05-06 · accession 0001610717-24-000231 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-07 | 2024-05-06 | CRVS | MILLER RICHARD A MD | Pres, CEO, Dir | P - Purchase | $1.73 | +577.6K | 577.6K | New | +$999.3K |
| D | 2024-05-07 | 2024-05-06 | CRVS | MILLER RICHARD A MD | Pres, CEO, Dir | P - Purchase | — | +559.1K | 559.1K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-06 | P | A | 577,634 | $1.73 | 577,634 | D | — | — | |
| 2 | Derivative | Warrant (Right to Buy) | 2024-05-06 | P | A | 559,073 | — | 559,073 | D | $3.50 · 2024-05-06 to 2025-06-30 | 559,073 Common Stock | (F2) Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312. |